Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial evaluates cetuximab's effectiveness in irinotecan-refractory colorectal cancer, suggesting significant clinical benefits.
Key Points
- This research aims to assess the effectiveness of cetuximab alone and in combination with irinotecan for treating irinotecan-refractory metastatic colorectal cancer.
- Evaluated cetuximab monotherapy and combination with irinotecan in a clinical setting.
- Focused on patients with irinotecan-refractory metastatic colorectal cancer.
- Cetuximab showed significant clinical activity as monotherapy.
- Combination therapy with irinotecan resulted in enhanced effectiveness compared to monotherapy.
Cite This Study
Cunningham et al. (2004) studied this question.